Stoke Therapeutics, Inc. (STOK) Stock Grade

About Stoke Therapeutics, Inc.'s fundamentals

Stoke Therapeutics is a biotech company with a market capitalization of $1.6 billion that reported exceptional revenue growth of 404.5% year-over-year, indicating rapidly expanding commercial traction. Despite this dramatic top-line expansion, the company operates at a net loss with a -3.7% net margin, and traditional profitability metrics like P/E ratio and return on equity are not applicable. Notably, the company generates positive free cash flow despite its accounting losses, suggesting that its cash burn is being managed through operational efficiency or non-cash charges. The company does not pay a dividend, which is typical for growth-stage biotech firms that reinvest capital into research and development.